Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Translation in Brief

The fate of NK cells

Differentiation states of CAR-transfected NK cells influence anticancer function

May 9, 2018 9:12 PM UTC

New research is elucidating the relationship between CAR-transfected NK cells’ differentiation states and their cancer-killing potential -- knowledge that Fate Therapeutics Inc. (NASDAQ:FATE) is leveraging for its own cell therapies.

In a study published in Cancer Immunology Research, a team that included Karl-Johan “Kalle” Malmberg explored how dynamic expression of various NK cell receptors affects the magnitude of the cells’ degranulation against tumor cell targets. Expression levels of these receptors change as highly proliferative immature NK cells age and reach a terminal differentiation state...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article